[go: up one dir, main page]

WO2008130949A3 - Modulation de l'expression de nurr1 dans une cellule - Google Patents

Modulation de l'expression de nurr1 dans une cellule Download PDF

Info

Publication number
WO2008130949A3
WO2008130949A3 PCT/US2008/060392 US2008060392W WO2008130949A3 WO 2008130949 A3 WO2008130949 A3 WO 2008130949A3 US 2008060392 W US2008060392 W US 2008060392W WO 2008130949 A3 WO2008130949 A3 WO 2008130949A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
nurrl
modulating
expression
nurr1 expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/060392
Other languages
English (en)
Other versions
WO2008130949A2 (fr
Inventor
Corinna Burger
Maria Estela Andres-Coke
Jose Antonio Fuentealba-Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2008130949A2 publication Critical patent/WO2008130949A2/fr
Publication of WO2008130949A3 publication Critical patent/WO2008130949A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de moduler l'expression de Nurr1 dans une cellule, y compris une cellule d'un sujet. Des inactivations somatiques de Nurr1 dans le mésencéphale de rats adultes ont été réalisées à l'aide de ribozymes délivrés par voie virale et la sur-expression de Nurr1 dans le cerveau de rats adultes a été obtenue à l'aide d'un virus adéno-associé (Adeno-Associated Virus : AAV) recombinant codant pour Nurr1.
PCT/US2008/060392 2007-04-16 2008-04-16 Modulation de l'expression de nurr1 dans une cellule Ceased WO2008130949A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91200207P 2007-04-16 2007-04-16
US60/912,002 2007-04-16

Publications (2)

Publication Number Publication Date
WO2008130949A2 WO2008130949A2 (fr) 2008-10-30
WO2008130949A3 true WO2008130949A3 (fr) 2009-04-16

Family

ID=39876148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/060392 Ceased WO2008130949A2 (fr) 2007-04-16 2008-04-16 Modulation de l'expression de nurr1 dans une cellule

Country Status (1)

Country Link
WO (1) WO2008130949A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066780A2 (fr) * 1999-04-30 2000-11-09 University Of Florida Ribozymes fournis par virus adeno-associes pour la decouverte de fonctions geniques
US20020049151A1 (en) * 2000-05-12 2002-04-25 Evelyn Murphy Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors
US20040052764A1 (en) * 2000-04-28 2004-03-18 Markus Hildinger Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066780A2 (fr) * 1999-04-30 2000-11-09 University Of Florida Ribozymes fournis par virus adeno-associes pour la decouverte de fonctions geniques
US20040052764A1 (en) * 2000-04-28 2004-03-18 Markus Hildinger Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US20020049151A1 (en) * 2000-05-12 2002-04-25 Evelyn Murphy Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors

Also Published As

Publication number Publication date
WO2008130949A2 (fr) 2008-10-30

Similar Documents

Publication Publication Date Title
WO2008073448A3 (fr) Formulations pharmaceutiques et leurs procédés de production
WO2008061109A3 (fr) Dérivés d'indazole utiles en tant que ligands des récepteurs de l'hormone concentrant la mélanine
MY195289A (en) Anti IL-36R Antibodies
WO2010045258A3 (fr) Modulateurs spirocycliques de gpr40
WO2011133890A8 (fr) Vecteurs aav ciblant le système nerveux central et leurs procédés d'utilisation
WO2008155059A3 (fr) Mélanges d'hydrocarbures et leur utilisation
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2010034032A3 (fr) Procédés pour préparer des compositions de polypeptide purifié
WO2021050614A3 (fr) Méthodes et compositions de modulation de l'interaction entre un virus adéno-associé (aav) et le récepteur d'aav (aavr) à des fins de bio-distribution modifiée d'aav
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
MX365818B (es) Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
WO2011159769A3 (fr) Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci
WO2010065491A3 (fr) Procédés de traitement de troubles inflammatoires
WO2010065709A3 (fr) Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
WO2011008495A3 (fr) Formulations d'arginase et procédés
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
WO2010021607A3 (fr) Préparation pharmaceutique
WO2003053358A3 (fr) Composes heterocycliques condenses et leurs substances analogues, modulant la fonction du recepteur hormonal nucleaire
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
WO2008115919A3 (fr) Procédés de préparation, de formulation et d'utilisation de valproate de lithium
MX2010002926A (es) Moduladores de tieno y furo-pirimidina del receptor h4 de histamina.
WO2008132021A3 (fr) Mélanges fongicides
WO2007130616A3 (fr) Polyamides destinés au traitement du papillomavirus humain
WO2010120874A3 (fr) Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08745900

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08745900

Country of ref document: EP

Kind code of ref document: A2